Month: April 2023

Baseline performance of the Company’s prototype has been fully benchmarked using commercial catalysts and is now available to evaluate the Company’s novel low-cost and high-performance catalyst technology. SANTA CLARITA, Calif., April 11, 2023 (GLOBE NEWSWIRE) — NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough green hydrogen generator that uses renewable energy and water to produce low-cost green hydrogen, today reported progress in the development of its prototype. The prototype benchmarking phase has been completed and is now available to evaluate the Company’s novel low-cost and high-performance catalyst technology. To establish the benchmark performance of current commercial catalysts, a systematic acidic water splitting test was conducted using a five-layer membrane electrode assembly (MEA) stack embedded with...

The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Friday, 12 May 2023, at 09:30, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm. Registration for the meeting will commence at 09:00. NOTIFICATION Shareholders who wish to attend the meeting must:       (i)      both be recorded in the share register maintained by Euroclear Sweden AB on the record date of Thursday, 4 May 2023; and       (ii)      not later than on Monday, 8 May 2023 have notified their attendance and possible advisors to the Company; either in writing via letter to Mendus AB (publ), “Annual General Meeting”, Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden, or by e-mail to info@mendus.com. The notification shall include full name, personal/corporate identity number, address,...

Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreementsModification of existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of nirsevimab and enhanced agility in the U.S. Existing collaboration agreement with AstraZeneca remains in place for nirsevimab activities ex-U.S.Paris, April 11, 2023. Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the U.S. Sanofi has simultaneously entered into a direct royalty agreement with Sobi to share a portion of U.S....

                  Sarah Dib is appointed General Counsel of Vallourec Meudon (France), 11 April 2023 – Vallourec announces that Sarah Dib has been appointed Group General Counsel. She succeeds Nathalie Joannes and joins the Executive Committee. Sarah Dib joined the Group in January 2023 as Head of Legal Affairs in charge of corporate governance and stock exchange law and Secretary to the Board of Directors, after having worked for several years as a lawyer in international law offices. Philippe Guillemot, Chairman of the Board of Directors & CEO, said: “I am delighted to announce Sarah’s expanded role as the Group’s General Counsel. Her corporate and stock exchange law expertise and international experience will help accelerate the implementation of the New Vallourec plan”. About Vallourec Vallourec...